glp 1 drugs hypothyroidism The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care GLP-1 Medications Infographic | Medidex
Description
doi:10.1530/eje.0.1460863 Lee S, Lee DY
Christopher K Rayner, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
Retatrutide administered once weekly subcutaneously for 12 weeks resulted in a dose-dependent placebo-adjusted weight loss of up to 8.96 kg in the highest dose group and a placebo-adjusted HbA1c reduction of up to 1.6% in a phase II trial in individuals with T2DM [125]
Friedrichsen M.H., Endahl L., Kreiner F.F., Goldwater R., Kankam M., Toubro S., Nygrd S.B
Research shows that a significant proportion of weight lost on GLP-1 medications can come from lean mass, with estimates suggesting up to 3040% of total weight loss may be muscle and bone density, rather than fat (Neeland et al
Were not going to oversell it its still investigational, its not approved, and anyone telling you otherwise is getting ahead of the evidence
